down arrow

Roivant Sciences Ltd.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: BMG762791017
USD
38.22
-0.77 (-1.97%)

Sep 22

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Incyte Corp.
Viatris, Inc.
Neurocrine Biosciences, Inc.
Alnylam Pharmaceuticals, Inc.
United Therapeutics Corp.
Repligen Corp.
Royalty Pharma Plc
Sarepta Therapeutics, Inc.
Walgreens Boots Alliance, Inc.
Roivant Sciences Ltd.
Horizon Therapeutics Plc

Why is Roivant Sciences Ltd. ?

1
Poor long term growth as Net Sales has grown by an annual rate of -35.82% and Operating profit at -263.66% over the last 5 years
2
The company has declared negative results for the last 8 consecutive quarters
  • NET PROFIT(9M) At USD -770.04 MM has Grown at -34.18%
  • DEBTORS TURNOVER RATIO(HY) Lowest at 0.02 times
  • OPERATING PROFIT(Q) Lowest at USD -365.78 MM
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 155.82%, its profits have fallen by -75.9%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Roivant Sciences Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Roivant Sciences Ltd.
155.82%
5.52
47.29%
S&P 500
16.0%
1.22
13.15%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-35.82%
EBIT Growth (5y)
-263.66%
EBIT to Interest (avg)
-138.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.04
Sales to Capital Employed (avg)
0.01
Tax Ratio
8.26%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
89.65%
ROCE (avg)
0
ROE (avg)
19.26%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.45
EV to EBIT
-11.90
EV to EBITDA
-11.94
EV to Capital Employed
-57.17
EV to Sales
1086.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-26.15%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
NET PROFIT(HY)

Higher at USD -506.97 MM

-25What is not working for the Company
NET PROFIT(9M)

At USD -770.04 MM has Grown at -34.18%

DEBTORS TURNOVER RATIO(HY)

Lowest at 0.02 times

OPERATING PROFIT(Q)

Lowest at USD -365.78 MM

PRE-TAX PROFIT(Q)

Lowest at USD -331.59 MM

RAW MATERIAL COST(Y)

Grown by 8.72% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -88.37 %

NET SALES(Q)

Lowest at USD 1.44 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -25,366.5 %

Here's what is working for Roivant Sciences Ltd.

Net Profit
Higher at USD -506.97 MM
than preceding 12 month period ended Jun 2026
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Here's what is not working for Roivant Sciences Ltd.

Net Sales
At USD 1.44 MM has Fallen at -30.17%
over average net sales of the previous four periods of USD 2.07 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (USD MM)

Operating Profit
Lowest at USD -365.78 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Operating Profit trend is quite negative

Operating Profit (USD MM)

Pre-Tax Profit
Lowest at USD -331.59 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Debtors Turnover Ratio
Lowest at 0.02 times and Fallen
In each half year in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Net Sales
Lowest at USD 1.44 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (USD MM)

Operating Profit Margin
Lowest at -25,366.5 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit
At USD -331.59 MM has Fallen at -21.45%
over average net sales of the previous four periods of USD -273.04 MM
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Debt-Equity Ratio
Highest at -88.37 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost
Grown by 8.72% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Footer loading